Results 41 to 50 of about 470,131 (305)
Minimal Residual Disease in Hematological Malignancies [PDF]
Accessible online at: www.karger.com/aha Do you prefer quality to quantity? This question has been asked for many years. It is well known that mathematics is the science of pure quantity but what about medicine? For many years, counting cells and identifying them by microscopic inspection have determined the number of normal or abnormal cells in ...
Pia, Raanani, Andreas, Hochhaus
openaire +2 more sources
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen +23 more
wiley +1 more source
Assessment of Minimal Residual Disease in Standard-Risk AML [PDF]
BACKGROUND: Despite the molecular heterogeneity of standard-risk acute myeloid leukemia (AML), treatment decisions are based on a limited number of molecular genetic markers and morphology-based assessment of remission.
Akiki, S +21 more
core
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis [PDF]
We analyzed 50 patients who achieved at least a very good partial response in the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), followed by ...
Bernardini, A +22 more
core +2 more sources
Clinical Insights Into Hypercalcemia of Malignancy in Childhood
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley +1 more source
Introduction: Minimal residual disease is an important independent prognostic factor that can identify poor responders among patients with acute lymphoblastic leukemia.
Francisco Danilo Ferreira Paula +7 more
doaj +1 more source
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment [PDF]
With contemporary therapeutic strategies in multiple myeloma, heretofore unseen depth and rate of responses are being achieved. These strategies have paralleled improvements in outcome of multiple myeloma patients.
Jinming Song +2 more
core +1 more source
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine +14 more
wiley +1 more source
Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute
Maura Rosane Valério Ikoma +5 more
doaj +1 more source
Prognostic role of minimal residual disease before and after hematopoietic stem cell transplantation in childhood acute lymphoblastic leukemia [PDF]
More than 80% of children with acute lymphoblastic leukemia (ALL) can be cured through intensive and risk-oriented chemotherapy protocols. Allogeneic hematopoietic stem cell transplantation (HSCT) is considered bene\ufb01cial for approximately 10% of the
Basso, Giuseppe +8 more
core

